Unknown PHASE2 INTERVENTIONAL 1-arm NCT03905317

Bevacizumab and Radiotherapy for Oligometastasis of Lung Adenocarcinoma With Negative Driver Gene

A Single-Armed Phase II Study of Radiation and Bevacizumab Maintenance Therapy for Oligometastasis of Lung Adenocarcinoma With Negative Driver Gene

Sponsor: Sun Yat-sen University

Conditions Lung Adenocarcinoma

Interventions Bevacizumab Injection chest radiation concurrent chemotherapy

Updated 5 times since 2019 Last updated: Apr 3, 2019 Started: Mar 1, 2019 Primary completion: Feb 28, 2022 Completion: Feb 28, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Lung Adenocarcinoma, this trial is ongoing. The trial is conducted by Sun Yat-sen University and has accumulated 5 data snapshots since 2019. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Mar 2022 — Jul 2024 [monthly]

Unknown Status PHASE2

Status: Recruiting → Unknown Status
Jan 2021 — Mar 2022 [monthly]

Recruiting PHASE2
May 2019 — Jan 2021 [monthly]

Recruiting PHASE2

First recorded

Mar 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sun Yat-sen University

Data source: Sun Yat-sen University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Guangzhou, China